CN112004925B - 具有降低的肝向性的AAV9和AAVrh74的杂合重组腺相关病毒血清型 - Google Patents
具有降低的肝向性的AAV9和AAVrh74的杂合重组腺相关病毒血清型 Download PDFInfo
- Publication number
- CN112004925B CN112004925B CN201980023352.XA CN201980023352A CN112004925B CN 112004925 B CN112004925 B CN 112004925B CN 201980023352 A CN201980023352 A CN 201980023352A CN 112004925 B CN112004925 B CN 112004925B
- Authority
- CN
- China
- Prior art keywords
- aav
- gene
- aav9
- hybrid
- capsid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305399.0 | 2018-04-05 | ||
| EP18305399 | 2018-04-05 | ||
| PCT/EP2019/058560 WO2019193119A1 (en) | 2018-04-05 | 2019-04-04 | HYBRID RECOMBINANT ADENO-ASSOCIATED VIRUS SEROTYPE BETWEEN AAV9 AND AAVrh74 WITH REDUCED LIVER TROPISM |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112004925A CN112004925A (zh) | 2020-11-27 |
| CN112004925B true CN112004925B (zh) | 2024-09-27 |
Family
ID=62063468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980023352.XA Active CN112004925B (zh) | 2018-04-05 | 2019-04-04 | 具有降低的肝向性的AAV9和AAVrh74的杂合重组腺相关病毒血清型 |
| CN201980095204.9A Pending CN113795574A (zh) | 2018-04-05 | 2019-10-04 | 具有降低的肝向性和增加的肌肉转导的AAV9和AAVrh74之间的肽修饰的杂合重组腺相关病毒血清型 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980095204.9A Pending CN113795574A (zh) | 2018-04-05 | 2019-10-04 | 具有降低的肝向性和增加的肌肉转导的AAV9和AAVrh74之间的肽修饰的杂合重组腺相关病毒血清型 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12037362B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3775173A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7374119B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20260093447A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112004925B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019249890B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112020020223A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3093347A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL277740A (cg-RX-API-DMAC7.html) |
| MA (1) | MA51353B1 (cg-RX-API-DMAC7.html) |
| TN (1) | TN2020000187A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019193119A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202005422B (cg-RX-API-DMAC7.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3097375A1 (en) * | 2018-04-27 | 2019-10-31 | Universitat Heidelberg | Modified aav capsid polypeptides for treatment of muscular diseases |
| EP3947427A1 (en) | 2019-03-25 | 2022-02-09 | Genethon | Production of large-sized quasidystrophins using overlapping aav vectors |
| CN114127088B (zh) * | 2019-04-23 | 2024-05-14 | 国家医疗保健研究所 | 变体衣壳蛋白和腺相关病毒aav变体及其药物组合物 |
| EP4031673A1 (en) | 2019-09-19 | 2022-07-27 | Genethon | Gene therapy expression system alleviating cardiac toxicity of fkrp |
| JP2022551986A (ja) * | 2019-10-16 | 2022-12-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | 修飾筋肉標的化組成物 |
| EP4073087A4 (en) * | 2019-11-08 | 2023-11-29 | The Board Of Regents Of The University Of Texas System | Recombinant adeno-associated viral vector for gene delivery |
| US20230047424A1 (en) * | 2019-12-09 | 2023-02-16 | Ucl Business Ltd | Gene therapy composition and treatment for myh7-linked cardiomyopathy |
| CA3156611A1 (en) | 2019-12-18 | 2021-06-24 | Serge Braun | Production of recombinant viral vectors from plant hairy roots |
| WO2021229255A1 (en) | 2020-05-14 | 2021-11-18 | Genethon | Tools and method for preventing a a¥ neutralization by antibodies |
| EP3913060A1 (en) | 2020-05-22 | 2021-11-24 | Genethon | Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy |
| CN116194474A (zh) | 2020-06-09 | 2023-05-30 | 吉尼松公司 | 遗传性扩张型心肌病的治疗 |
| CA3185499A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies |
| JP2023528661A (ja) | 2020-06-09 | 2023-07-05 | ジェネトン | 拡張型心筋症の処置における使用のためのnrf2活性化剤 |
| CN115996758A (zh) | 2020-06-19 | 2023-04-21 | 吉尼松公司 | 使sgcg在肌肉和心脏中充分表达的基因治疗表达系统 |
| US20230242905A1 (en) | 2020-07-03 | 2023-08-03 | Genethon | Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping |
| BR112023000305A2 (pt) | 2020-07-10 | 2023-03-21 | Genethon | Promotor, sistema de expressão e composição farmacêutica |
| US12668814B2 (en) | 2020-07-22 | 2026-06-30 | The Broad Institute, Inc. | Engineered muscle targeting compositions |
| CN116096431A (zh) * | 2020-09-10 | 2023-05-09 | 吉尼松公司 | 肽修饰的aav衣壳 |
| EP4222263A1 (en) | 2020-09-29 | 2023-08-09 | Genethon | Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof |
| EP4255457A4 (en) * | 2020-12-03 | 2025-05-21 | University of Massachusetts | DEVELOPMENT OF NEW GENE THERAPEUTIC AGENTS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA |
| WO2022143623A1 (zh) * | 2020-12-29 | 2022-07-07 | 江苏金斯瑞蓬勃生物科技有限公司 | 高分散性的hek293t细胞株及其筛选方法 |
| CA3210955A1 (en) * | 2021-02-09 | 2022-08-18 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
| WO2022204476A1 (en) | 2021-03-26 | 2022-09-29 | The Board Of Regents Of The University Of Texas System | Nucleotide editing to reframe dmd transcripts by base editing and prime editing |
| WO2022226301A1 (en) * | 2021-04-23 | 2022-10-27 | The University Of North Carolina At Chapel Hill | Chimeric heart tropic aav capsids |
| WO2023012313A1 (en) | 2021-08-04 | 2023-02-09 | Genethon | Hybrid promoters for gene expression in muscles and in the cns |
| CN115232818B (zh) * | 2021-09-18 | 2025-10-21 | 南京启真基因工程有限公司 | 构建dok7基因突变的先天性肌无力模型猪核移植供体细胞的基因编辑系统及其应用 |
| US20230211014A1 (en) * | 2021-12-29 | 2023-07-06 | Genetic Cures for Kids Inc. | AAV Gene Therapy for Spastic Paraplegia |
| CN114276419B (zh) * | 2021-12-30 | 2023-11-17 | 上海勉亦生物科技有限公司 | 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用 |
| CN119317718A (zh) | 2022-01-25 | 2025-01-14 | 宾夕法尼亚州大学信托人 | 用于改善心脏转导和肝脏去靶向的aav衣壳 |
| CN114657152A (zh) * | 2022-03-31 | 2022-06-24 | 苏州博腾生物制药有限公司 | 一种新型aav血清型及其制备方法 |
| CN120590489A (zh) * | 2022-04-12 | 2025-09-05 | 合肥星眸生物科技有限公司 | 一种融合型腺相关病毒及其应用 |
| WO2023237731A1 (en) | 2022-06-09 | 2023-12-14 | Genethon | N-terminal truncated gde for the treatment of glycogen storage disease iii |
| FI4536686T3 (fi) | 2022-06-10 | 2026-01-13 | Genethon | Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi |
| JP2025532754A (ja) | 2022-10-07 | 2025-10-03 | ジェネトン | 抗fap car-t細胞を使用する骨格筋ミオパチーの免疫療法 |
| CA3267327A1 (en) | 2022-10-12 | 2024-04-18 | Genethon | AAV HYBRID VECTOR ENHANCING TRANSGENE EXPRESSION IN THE LIVER |
| CN116041443B (zh) * | 2022-12-30 | 2023-09-22 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| AU2024221161A1 (en) * | 2023-02-17 | 2025-08-28 | Biogen Ma Inc. | Rgd-containing peptides for delivering payloads |
| CN116693633B (zh) * | 2023-02-21 | 2023-12-22 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| WO2024188913A1 (en) | 2023-03-10 | 2024-09-19 | Genethon | Induction of immune tolerance by aav vector comprising the combination of a liver detargeted capsid and a tandem liver-muscle specific promoter |
| WO2025003477A1 (en) | 2023-06-29 | 2025-01-02 | Genethon | N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii |
| WO2025015036A1 (en) * | 2023-07-10 | 2025-01-16 | Kate Therapeutics, Inc. | Aav gene therapy approach for treating lgmd2b/dysferlinopathy |
| WO2025017168A1 (en) | 2023-07-19 | 2025-01-23 | Genethon | Novel optimized utrophin micro-genes |
| WO2025017169A1 (en) | 2023-07-20 | 2025-01-23 | Genethon | Novel mididystrophins |
| CN117964715B (zh) * | 2023-07-21 | 2025-01-24 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| WO2025072698A2 (en) * | 2023-09-27 | 2025-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Aav9 vectors and capsid polypeptides for use in treating cns disorders |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025137378A1 (en) * | 2023-12-20 | 2025-06-26 | Aavantibio, Inc. | Aav capsid engineering for cardiac and/or musculoskeletal gene therapy |
| WO2025133247A1 (en) | 2023-12-21 | 2025-06-26 | Genethon | Methods for aav vector re-administration |
| WO2025232917A1 (en) * | 2024-05-10 | 2025-11-13 | Hangzhou Jiayin Biotech Ltd. | Novel liver detargeted aav variants and uses thereof |
| WO2026017727A1 (en) | 2024-07-16 | 2026-01-22 | Genethon | Alternative barcoding method to assess transduction efficiency of aav vectors |
| WO2026041758A1 (en) | 2024-08-22 | 2026-02-26 | Genethon | Modified aav capsid with enhanced transduction efficiency |
| WO2026064736A1 (en) * | 2024-09-23 | 2026-03-26 | Carbon Biosciences, Inc. | Parvovirus compositions and related methods for gene therapy |
| WO2026064739A1 (en) * | 2024-09-23 | 2026-03-26 | Carbon Biosciences, Inc. | Parvovirus compositions and related methods for gene therapy |
| WO2026122921A1 (en) | 2024-12-05 | 2026-06-11 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| CN120842333A (zh) * | 2025-06-20 | 2025-10-28 | 上海朗昇生物科技有限公司 | 工程化的腺相关病毒衣壳蛋白和载体及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105324392A (zh) * | 2013-04-20 | 2016-02-10 | 全国儿童医院研究所 | 外显子2靶向U7snRNA多核苷酸构建体的重组腺相关病毒递送 |
| CN105518145A (zh) * | 2013-07-12 | 2016-04-20 | 费城儿童医院 | Aav载体和用于抗aav(腺相关病毒)中和抗体的检测 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| EP2396343B1 (en) * | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| CN103502458B (zh) | 2011-02-17 | 2016-11-16 | 宾夕法尼亚大学托管会 | 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法 |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| JP6342886B2 (ja) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
| EP2660325A3 (en) | 2012-05-02 | 2014-02-12 | Christian Medical College | AAV vectors and corresponding nucleotide sequences and methods |
| JP2016517278A (ja) * | 2013-03-15 | 2016-06-16 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 |
| NZ716102A (en) * | 2013-07-22 | 2021-12-24 | The Children’S Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2016049230A1 (en) | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
| WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| AU2017234929B2 (en) | 2016-03-18 | 2024-05-02 | The Children's Hospital Of Philadelphia | Therapeutic for treatment of diseases including the central nervous system |
| JP6994018B2 (ja) * | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| MX2020010465A (es) * | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. |
-
2019
- 2019-04-04 JP JP2020554181A patent/JP7374119B2/ja active Active
- 2019-04-04 CA CA3093347A patent/CA3093347A1/en active Pending
- 2019-04-04 WO PCT/EP2019/058560 patent/WO2019193119A1/en not_active Ceased
- 2019-04-04 MA MA51353A patent/MA51353B1/fr unknown
- 2019-04-04 AU AU2019249890A patent/AU2019249890B2/en active Active
- 2019-04-04 TN TNP/2020/000187A patent/TN2020000187A1/en unknown
- 2019-04-04 KR KR1020267018842A patent/KR20260093447A/ko active Pending
- 2019-04-04 CN CN201980023352.XA patent/CN112004925B/zh active Active
- 2019-04-04 EP EP19714230.0A patent/EP3775173A1/en active Pending
- 2019-04-04 KR KR1020207032024A patent/KR20210015770A/ko not_active Ceased
- 2019-04-04 US US16/981,086 patent/US12037362B2/en active Active
- 2019-04-04 BR BR112020020223-1A patent/BR112020020223A2/pt unknown
- 2019-10-04 JP JP2021558887A patent/JP2022526405A/ja not_active Withdrawn
- 2019-10-04 CA CA3134183A patent/CA3134183A1/en not_active Withdrawn
- 2019-10-04 US US17/600,715 patent/US20220228167A1/en not_active Abandoned
- 2019-10-04 KR KR1020217031502A patent/KR20210153047A/ko not_active Withdrawn
- 2019-10-04 CN CN201980095204.9A patent/CN113795574A/zh active Pending
- 2019-10-04 WO PCT/EP2019/076958 patent/WO2020200499A1/en not_active Ceased
- 2019-10-04 BR BR112021019821A patent/BR112021019821A2/pt not_active Application Discontinuation
- 2019-10-04 EP EP19782603.5A patent/EP3947653A1/en not_active Withdrawn
- 2019-10-04 AU AU2019439673A patent/AU2019439673A1/en not_active Withdrawn
-
2020
- 2020-08-31 ZA ZA2020/05422A patent/ZA202005422B/en unknown
- 2020-10-01 IL IL277740A patent/IL277740A/en unknown
-
2021
- 2021-10-03 IL IL286926A patent/IL286926A/en unknown
-
2024
- 2024-06-06 US US18/735,636 patent/US20240317814A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105324392A (zh) * | 2013-04-20 | 2016-02-10 | 全国儿童医院研究所 | 外显子2靶向U7snRNA多核苷酸构建体的重组腺相关病毒递送 |
| CN105518145A (zh) * | 2013-07-12 | 2016-04-20 | 费城儿童医院 | Aav载体和用于抗aav(腺相关病毒)中和抗体的检测 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112004925A (zh) | 2020-11-27 |
| KR20260093447A (ko) | 2026-06-19 |
| KR20210015770A (ko) | 2021-02-10 |
| IL277740A (en) | 2020-11-30 |
| JP2022526405A (ja) | 2022-05-24 |
| CA3093347A1 (en) | 2019-10-10 |
| JP2021520203A (ja) | 2021-08-19 |
| US20220228167A1 (en) | 2022-07-21 |
| AU2019249890A1 (en) | 2020-09-24 |
| CN113795574A (zh) | 2021-12-14 |
| BR112021019821A2 (pt) | 2021-12-07 |
| WO2019193119A1 (en) | 2019-10-10 |
| WO2020200499A1 (en) | 2020-10-08 |
| US20240317814A1 (en) | 2024-09-26 |
| US20210107948A1 (en) | 2021-04-15 |
| BR112020020223A2 (pt) | 2021-01-19 |
| KR20210153047A (ko) | 2021-12-16 |
| MA51353A1 (fr) | 2021-09-30 |
| ZA202005422B (en) | 2023-03-29 |
| TN2020000187A1 (en) | 2022-04-04 |
| NZ767516A (en) | 2024-11-29 |
| IL286926A (en) | 2021-10-31 |
| EP3947653A1 (en) | 2022-02-09 |
| MA51353B1 (fr) | 2022-09-30 |
| AU2019249890B2 (en) | 2024-10-10 |
| JP7374119B2 (ja) | 2023-11-06 |
| EP3775173A1 (en) | 2021-02-17 |
| RU2020136195A (ru) | 2022-05-06 |
| US12037362B2 (en) | 2024-07-16 |
| AU2019439673A1 (en) | 2021-10-07 |
| CA3134183A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112004925A (zh) | 具有降低的肝向性的AAV9和AAVrh74的杂合重组腺相关病毒血清型 | |
| EP4211231B1 (en) | Peptide-modified aav capsid | |
| ES2844181T3 (es) | Vectores rAAV con alta eficiencia de transducción, composiciones y métodos de uso | |
| EP2940131B1 (en) | Aav variant | |
| WO2021219762A1 (en) | Use of a synthetic aav capsid for gene therapy of muscle and central nervous system disorders | |
| CN116209768A (zh) | 用于通过高变区交换工程化新杂合aav衣壳的方法 | |
| EP4536686B1 (en) | Peptide-modified aav capsid with enhanced muscle transduction efficiency | |
| EP3952920A1 (en) | Hybrid promoters for muscle expression | |
| HK40091751A (en) | Peptide-modified aav capsid | |
| WO2026041758A1 (en) | Modified aav capsid with enhanced transduction efficiency | |
| BR112023004176B1 (pt) | Proteína de capsídeo de aav, polinucleotídeo, plasmídeo recombinante, partícula de vetor de aav, seu uso para tratamento de doenças musculares e composição farmacêutica | |
| CN105358690A (zh) | 启动子组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |